AbbVie drops CytomX partnership, leaving PhII program in the air
AbbVie is winding down its collaboration with CytomX seven years after first embarking on a search for conditionally activated cancer immunotherapy programs.
CytomX will be weighing its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie decided not to advance the drug into additional studies, the biotech disclosed in its quarterly update. The Big Pharma partner also served notice to terminate their licensing deal, which dates back to 2016, on the same day.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters